A total of 551 postmenopausal women with breast cancer who completed tamoxifen treatment and were undergoing daily letrozole treatment were randomized to either upfront ( 274 patients ) or delayed ( 277 patients ) ZA at a dose of 4 mg intravenously every 6 months .